arrow
C

Clare Turnbull

Institute of Cancer Research
H指数:68
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exome-wide analysis of rare deleterious variants in 3,569 sarcoma cases and 21,788 controls from multiple international data sources reveals no novel susceptibility genes

对来自多个国际数据源的3,569例肉瘤病例和21,788例对照的基因组外显子范围分析,未发现新的易感基因

2026-10-210
OAAI
Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success☆

癌症预防药物的随机III期临床试验:一项系统综述和试验成功的预测<a class="anchor anchor-primary" href="#fn1" name="bfn1" data-sd-ui-side-panel-opener="true" data-xocs-content-type="reference" data-xocs-content-id="fn1"><span class="anchor-text-container"><span class="anchor-text"><sup>☆</sup></span></span></a>

2026-09-090
OAAI
The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS

为患有新诊断浸润性乳腺癌或高级别DCIS的女性扩展对高外显率生殖系基因检测的访问权限的影响

2026-08-010
PRE
Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a ‘BRCA-DIRECT’ mainstreaming pathway

对3552例未经选择的NHS乳腺癌患者进行常规生殖系遗传检测:为检测标准提供证据并实施“BRCA-DIRECT”常规化路径

2026-07-090
OA
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants

ACMG/AMP变异整理指南中关于体细胞PALB2序列变异分析的规定

2025-09-170
OAAI
Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer) and renal cancer

量化综合征表型(PP4)特异性证据:大规模整合来自HLRCC(遗传性平滑肌瘤病和肾细胞癌)及肾癌诊断实验室检测的罕见生殖系FH变异

2025-09-040
OAAI
Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations

基于临床-公共卫生效用的主流肿瘤学中乳腺癌胚系多基因-panel检测:ESMO精准肿瘤学工作组建议

2025-06-150
PREAI
Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records

BRCA1和BRCA2致病性变异携带者中,有乳腺癌病史者行双侧输卵管卵巢切除术的长期健康结局:一项基于关联电子健康记录的回顾性队列研究

2025-05-080
OA
Meta-analysis of Germline Whole-exome Sequencing in 1435 Cases of Testicular Germ Cell Tumour to Evaluate Disruptive Mutations Under Dominant, Recessive, and X-linked Inheritance Models

1435例睾丸生殖细胞肿瘤种系全外显子测序的Meta分析,以评估显性,隐性和X连锁遗传模型下的破坏性突变

2025-03-010
OAAI
Identification of genes associated with testicular germ cell tumor susceptibility through a transcriptome-wide association study

通过全转录组关联研究鉴定与睾丸生殖细胞肿瘤易感性相关的基因

2025-02-010
OAAI
Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)

使用癌症表型性别特异性来实现对卵巢小细胞癌,高钙血症型 (SCCOHT) 的SMARCA4致病变体的无偏外显率估计

2025-01-010
PRE
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants

用于分析种系ATM序列变体的ACMG/AMP变体管理指南的规范

2024-11-010
OAAI
ESMO Recommendations on clinical reporting of genomic test results for solid cancers

ESMO关于实体癌基因组检测结果临床报告的建议

2024-11-010
OAAI
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial

BRCA-英国乳腺肿瘤学环境中诊断性种系基因检测的直接数字途径: 一项随机,非劣效性试验

2024-10-011
OA
Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel
2024-09-0112
OAAI
Saturation genome editing of BAP1 functionally classifies somatic and germline variants
2024-07-050
OA